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EDITORIAL COMMENT
Hypertension, Angiotensin II,
Aldosterone, and Race*
Ori Ben-Yehuda, MD, FACC
San Diego, California
One in four Americans has hypertension. Improvements in
hypertension awareness and treatment in the 1970s and
1980s have contributed to a nearly 60% decline in the
age-adjusted death rates from stroke. Still, since 1993,
stroke rates have risen, along with the prevalence of heart
failure and end-stage renal disease (1). Moreover, in approx-
imately two-thirds of hypertensive patients, blood pressure
(BP) is not fully controlled. The challenge of hypertension
is particularly severe in the African American community,
which is disproportionately affected. Not only is the preva-
lence higher (32% of African Americans vs. 23% for
non-African Americans), but also the complications of
uncontrolled high BP are up to four times more frequent in
African Americans (2–4). Treatment gaps are also greater in
the African American population.
See page 1148
In this issue of the Journal, Flack et al. (5) report on the
efficacy and tolerability of a novel antihypertensive agent,
the selective aldosterone antagonist eplerenone, which was
recently approved by the Food and Drug Administration for
the treatment of hypertension. In the study by Flack et al.
(5), eplerenone was tested (at 50 to 200 mg/day) versus
placebo, as well as versus the angiotensin receptor blocker
(ARB) losartan (at 50 to 100 mg/day), in hypertensive black
patients (because the trial included patients in South Africa
as well as the U.S., the term black rather than African
American was used to describe the study population). The
effects of the two agents as monotherapy on black patients
were also compared with the effects on white patients.
Although the two agents had similar efficacy in white
patients, eplerenone was significantly more efficacious than
losartan in black patients.
The availability of a novel aldosterone inhibitor comes at
a time of renewed attention to the role of aldosterone in
cardiovascular disease (6). Aldosterone receptors have been
found in the brain, myocardium, and vasculature, and
aldosterone has been linked in animal models with both
vascular and myocardial fibrosis (7). In both patients with
hypertension and patients with heart failure, aldosterone
levels are elevated despite complete long-term inhibition of
vascular angiotensin-converting enzyme (ACE), pointing to
a phenomenon of aldosterone escape (8). Whether aldoste-
rone escape occurs in the setting of ARB use is unclear,
particularly in humans, with one animal study suggesting
that it does not (9).
News of more efficacious treatments of hypertension, in
general, and in African Americans in particular, is, of
course, to be welcomed, and the results of monotherapy
with eplerenone in this study confirm its efficacy. The
relative lack of efficacy of losartan as monotherapy in black
patients documented in the study by Flack et al. (5) is not
surprising, as black hypertensive patients, who are more
likely to have low renin levels, are known to be less
responsive to monotherapy with ARBs as well as ACE
inhibitors (10). Indeed, in a previously published study of
440 hypertensive African Americans, Flack et al. (11)
demonstrated that losartan monotherapy (titrated up to 150
mg/day) reduced sitting diastolic blood pressure (DBP) by
only 6.6 mm Hg and systolic blood pressure (SBP) by 6.4
mm Hg (11). Moreover, losartan monotherapy had a flat
dose-response curve in this population. When low-dose
hydrochlorothiazide (12.5 to 25 mg) was added to 50 to 100
mg of losartan, however, BP reductions of 10.8 mm Hg in
DBP and 16.8 mm Hg in SBP were achieved. Therefore,
although monotherapy with losartan (and presumably other
ARBs as well) is unlikely to achieve adequate BP reductions
in the low-renin African American hypertensive patient, the
addition of a low-dose diuretic can robustly lower BP. The
use of a diuretic is particularly important in the salt-sensitive
low-renin patient who continues to consume a high-sodium
diet.
A diuretic only arm was not included in either the
eplerenone/losartan (5) study or the previously published
losartan/hydrochlorothiazide African American study (11).
Given the low cost of diuretics as well as the data for stroke
reduction with diuretics, the lack of comparative data in
both studies to diuretics is regrettable. Still, for both
eplerenone and losartan, additive efficacy when added to a
diuretic based regimen has been demonstrated. Given that
most hypertensive patients (even those in stage I or II)
require two or more medications to achieve their BP goal,
combination therapy will continue to be necessary, and both
eplerenone and losartan, therefore, are useful agents.
Reduction in BP can be viewed as a surrogate end point.
Ultimately, the results of therapy on morbidity and mortal-
ity are of much greater importance. In this regard, the
recently published Losartan Interventions For End points
reductions (LIFE) study (12) sheds important light on the
importance of angiotensin II and its blockade and points to
potentially important differences among BP medications
beyond reductions per se in BP. In the LIFE study, the
efficacy of a losartan-based regimen was compared with an
atenolol-based regimen in 9,193 patients with hypertension
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and left ventricular hypertrophy (LVH). Although BP
reductions were identical in the two active treatment arms,
losartan was superior to atenolol with greater regression in
LVH and a 25% reduction in stroke.
The results of the LIFE study, conducted against an
active beta-blocker comparator, point to the importance of
angiotensin II and its blockade in cardiovascular disease.
Angiotensin II has been implicated in endothelial dysfunc-
tion, oxidative stress, medial arterial hypertrophy, LVH,
and atherosclerosis among others (13). Blockade of angio-
tensin II at its type 1 (AT-1) receptor has been shown to
improve endothelial function, reduce arterial medial hyper-
trophy (14), and in a primate model, markedly reduce
atherosclerosis (15). Thus, theoretical, experimental, and
outcome data exist to support inhibiting the renin-
angiotensin system.
However, the situation in African Americans is more
complicated. As a group, African American hypertensive
patients have lower plasma renin activity and are more
salt-sensitive, with diminished pressure natriuresis response.
Intrarenal levels of angiotensin II are, however, actually
elevated leading to intrarenal vasoconstriction (16). More-
over, African American patients have been shown to re-
spond to higher doses of ACE inhibitors or to combinations
with diuretics. A surprising finding in the LIFE study,
however, was that although the benefit of losartan versus
atenolol was maintained in 23 of 24 predefined subgroups,
in black patients, who comprised 6% of the study popula-
tion, atenolol was superior (17). Given the relatively small
sample size, larger studies need to be done to address this
issue.
Treatment with aldosterone antagonists results in an
increase in renin levels and, conceivably, in angiotensin II.
While animal data suggest that some of the effects of
angiotensin II outside the kidney are mediated by aldoste-
rone, whether outcomes with a drug such as eplerenone
would be comparable to those seen with ACE inhibitors
and ARBs remains to be established. Moreover, the con-
comitant use of aldosterone blockade with ARB or ACE
blockade has yet to be fully addressed. Conceivably, com-
bination therapy with both eplerenone and an ARB or ACE
inhibitor would provide for more complete neurohormonal
blockade. Hyperkalemia, however, a well-recognized side
effect of both eplerenone and ACE/ARBs, was increased in
combination studies. Particularly in diabetics with albumin-
uria there was an unacceptably high incidence of hyperka-
lemia with eplerenone therapy either alone or in combina-
tion with ACE inhibition (18). Although aldosterone
blockade with spironolactone has gained acceptance in
combination with ACE inhibition in the treatment of heart
failure, the less frequent monitoring given to patients with
hypertension compared with patients with heart failure
mandates caution in using ACE/ARBs in combination with
aldosterone blocking agents such as eplerenone in the
treatment of hypertension even in the non-diabetic. Given
the disparities in health care access, this issue is particularly
relevant in the African American population.
The advantage of eplerenone over the aldosterone antag-
onist spironolactone, which is also indicated for the treat-
ment of hypertension, is in its greater selectivity. In vitro,
eplerenone was shown to be highly selective for the aldo-
sterone receptor, with low binding to progesterone (1%)
and androgen (0.1%) receptor (19). Thus, whereas spirono-
lactone is associated with a gynecomastia rate of 6.9% in
hypertensive males, the incidence of gynecomastia or mas-
todynia was 1.6% in eplerenone studies (18) lasting longer
than six months. In females, abnormal vaginal bleeding was
reported in 0.8% on eplerenone in controlled studies lasting
6 months, and in 2.1% in open-label, long-term studies.
Thus, while the side effect profile of eplerenone is decidedly
more favorable than spironolactone, the potential for hor-
monal side effects is not entirely eliminated.
Finally, important but thorny issues regarding the use of
race in clinical studies are raised by the study by Flack et al.
(5). Some have criticized studies that use skin color and
self-designation of racial affiliation as being instances of
“racial profiling” (20). Still, it is undeniable that disease
prevalence and responses to therapy often differ in different
ethnic and racial populations, with hypertension and its
effects in African Americans being a prime example. Re-
cently, the increased incidence of two synergistic polymor-
phisms of the beta1- and alpha2C-adrenergic receptors in
black patients allowed researchers to link the presence of
these polymorphisms to a markedly increased risk of the
development of heart failure (21). Indeed, the increased
frequency in blacks of polymorphisms affecting the adren-
ergic system may explain their overall better response to
therapy with beta-blockade versus ARBs as seen in the
LIFE study. Similarly, whereas carvedilol was equally effi-
cacious in white and black patients with heart failure (22),
enalapril was less effective in black patients compared with
white patients (23). Indeed, it is precisely because of these
differences that researchers are mandated to enroll a racially
diverse population in clinical studies.
Whether a study is primarily aimed at studying a specific
racial group versus another or subgroup analysis is used to
assess the response in different racial populations, important
and potentially useful clinical information is generated.
That there are differences between racial groups in preva-
lence of disease or in response to therapy is ultimately,
however, due to the different frequency of genetic and
environmental factors among different groups. The use of
racial designations in clinical studies is only an imprecise
and problematic surrogate for genetic polymorphisms as
well as the social, economic, and other factors that may
influence biology. Therefore, there is a risk, particularly in
the genetically very heterogeneous population of the U.S., of
assuming a certain biologic effect simply on the basis of race.
The genetic revolution may ultimately provide us with
the tools to determine the best therapy for a given patient in
a racially blind manner. We could then tailor therapy based
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on individual determinants rather than racial and social
ones. In the meantime, we should be cautious in our
application of results based on race-based studies in clinical
practice.
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